Tissue Regenix Group PLC DermaPure manufacturing at CellRight Facility (8532L)
April 24 2018 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 8532L
Tissue Regenix Group PLC
24 April 2018
Tissue Regenix Group plc
Successful completion of technical transfer for DermaPure
manufacturing at CellRight Facility
First product sales from inhouse manufacturing
Leeds, 24 April 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or "The Group") the regenerative medical devices company
is pleased to announce that, following the successful completion of
the manufacturing technical transfer, it has commenced sales of
DermaPure products processed at the CellRight Technologies
("CellRight") facility in San Antonio, Texas.
The completion of the transfer of DermaPure, ahead of schedule,
brings a number of benefits to the Group including:
-- Expand manufacturing capabilities to meet increasing demands
from Global sales and distribution partners
-- Improves supply chain production efficiency, and product life cycle management
-- Process enhancements increase DermaPure's shelf life from two to three years
-- Inhouse manufacturing will facilitate the augmentation of its product portfolio
Commercialised under the recently rebranded TRX BioSurgery
division, DermaPure, is being utilised in an increased number of
clinical applications including acute and chronic wound care,
orthopaedic trauma, dental, and following the exclusive
distribution agreement with ARMS medical, urogynaecology and
urology.
Steve Couldwell, CEO, Tissue Regenix Group commented: "We are
extremely encouraged by the continued progress integrating
CellRight into the Tissue Regenix Group. Completing the transfer of
DermaPure manufacturing to our CellRight facility was achieved,
ahead of schedule, and incorporated significant process
improvements which is a testament to the CellRight team. This is an
important strategic milestone in the Group's long-term commercial
strategy and I am pleased that the operational synergies are
developing as expected. As a result we now have greater flexibility
to explore new product opportunities to meet patient demand,
expanding the markets we operate in with a reduced manufacturing
risk profile."
For more Information:
Tissue Regenix Group plc Tel: 0330 430 3073
Caitlin Pearson Head of Communications / 07920272 441
---------------------------------------- -------------------
Jefferies International Ltd Tel: 020 7029 8000
Simon Hardy / Christopher Binks
---------------------------------------- -------------------
FTI Consulting Tel: 0203 727 1000
Brett Pollard / Mo Noonan/ Mary
Whittow
======================================== ===================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFXLLLVZFLBBX
(END) Dow Jones Newswires
April 24, 2018 02:00 ET (06:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2023 to Aug 2024